TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05661617

Intervention type: DIAGNOSTIC_TEST
Intervention: Nine Hole Peg Test, Purdue Pegboard Test, Box and Block Test
Description: Research participants were tested in one meeting after giving informed consent, answering a few short questions regarding health status and filling out a short questionnaire using the Czech extended version of the manual for the Nine Hole Peg Test, Purdue Pegboard Test and Box and Block Test, and always according to a predetermined order. Intentionally, all research participants from experimental group with a dominant right upper limb will be tested as if they were left-handed, and vice versa.~All research participants from normative study were tested normally according to the Czech extended manuals for those tests.

Intervention type: DIAGNOSTIC_TEST
Intervention: Nine Hole Peg Test, Purdue Pegboard Test, Box and Block Test
Description: Research participants were tested in one meeting after giving informed consent, answering a few short questions regarding health status and filling out a short questionnaire using the Czech extended version of the manual for the Nine Hole Peg Test, Purdue Pegboard Test and Box and Block Test, and always according to a predetermined order. Intentionally, all research participants from experimental group with a dominant right upper limb will be tested as if they were left-handed, and vice versa.~All research participants from normative study were tested normally according to the Czech extended manuals for those tests.
Study: NCT05969158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag
Description: After screening, patients who were treated with XPO-1 inhibitor Selinexor combined with chemotherapy and developed chemotherapy-related thrombocytopenia (CIT) after treatment and met the secondary prevention criteria were eligible for inclusion criteria.~The platelet reduction after the previous chemotherapy was used as the control group:~The patients did not routinely receive prophylactic platelet elevation therapy after the previous Selinexor combined chemotherapy, and when PLT \< 50×109/L.~Platelet reduction after chemotherapy in secondary prevention unit was used as the experimental group:~The subjects will initiate treatment with 5 mg hetrombopag once a day, starting orally 5 days before chemotherapy, take it for 5 days (D-5-D-1), and continue taking it orally for 5 days after chemotherapy (D1-D5).
Study: NCT05678881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose RLS103
Description: 8 mg CBD inhaled powder

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo inhaled powder
Description: placebo inhaled powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose RLS103
Description: 4 mg CBD inhaled powder (open label)
Study: NCT05535296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk profile
Description: Compiliation of risk profile based on fitness, strength, mobility, balance, posture, physical activity level, weight and pain. Advice based on the above and support in goal-setting.
Study: NCT05255367

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: (poly)phenols rich foods
Description: Prior to start the intervention (initial time of the study) the volunteers will follow their habitual diet during 30 days as a control period, and then they will start with the intervention period (baseline) following their habitual diet supplemented with (poly)phenol rich products during 60 days (after intervention).~At the beginning of the study (initial time), at the beginning of the intervention (baseline) and at the end of the intervention (after the intervention) with rich (poly)phenols foods, biological samples (blood, urine and feces) and anthropometric measurements will be taken. In addition, the participants will record the food intake weekly with a 24 h dietary-recall form.
Study: NCT05833633

Intervention type: DIAGNOSTIC_TEST
Intervention: MUSCLE MAGNETIC RESONANCE IMAGING (MRI)
Description: To assess longitudinally at baseline and 1 year later changes on muscle MRI, genetic test, functional motor and respiratory assessments in the DMD group with different type of small mutations and the DMD group with non sense mutations treated with Atarulen in order to better define natural history of these patients. .

Intervention type: DIAGNOSTIC_TEST
Intervention: MUSCLE MAGNETIC RESONANCE IMAGING (MRI)
Description: To assess longitudinally at baseline and 1 year later changes on muscle MRI, genetic test, functional motor and respiratory assessments in the DMD group with different type of small mutations and the DMD group with non sense mutations treated with Atarulen in order to better define natural history of these patients. .
Study: NCT05165771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-5718
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-5718
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match GS-5718
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match GS-5718
Description: Tablets administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match GS-5718
Description: Tablets administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match GS-5718
Description: Tablets administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib 5 mg
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match Tofacitinib
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match Tofacitinib
Description: Tablets administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match Tofacitinib
Description: Tablets administered orally
Study: NCT05682716

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Controlled low central venous pressure (CLCVP) technology
Description: Controlled low central venous pressure (CLCVP) technology: after cardiopulmonary bypass, pumping nitroglycerin (0.2-1 ug/kg \* min) and other methods until the end of surgery to maintain the central venous pressure below 10 mmHg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Description: nitroglycerin (0.2-1 ug/kg \* min)
Study: NCT05483777

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRF
Description: Platelet-rich fibrin preparation and application technique will applied to the experimental group.
Study: NCT05764785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MentorPRO
Description: MentorPRO is a novel application and web platform for mentoring programs that allows students to set goals, track their challenges, and find just-in time resources, while connecting to a mentor for personalized support and progress monitoring.
Study: NCT05809375

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coping Skills Training
Description: In the intervention, it was acted in a way to include the educational content determined by the International Headache Association and with a problem-solving perspective. The coping skills training contents in the literature were combined, and the CST prepared by including the most used and related contents will be given. CST includes a targeted therapy specifically developed for this study to address the needs and expectations of individuals with migraine. The targeted CST was designed by the authors, consisting of an occupational therapist, and two physiotherapists with clinical, and academic experience. It is planned as a total of eight sessions, and two sessions per week. CST includes giving information about migraine, activity tempo, progressive muscle relaxation exercise, stress management, social participation, leisure time management, general evaluation of the program, and home program.
Study: NCT04947423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPI-386 Nasal Gel
Description: Subjects will self-administer DPI-386 Nasal Gel or Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will self-administer DPI-386 Nasal Gel or Placebo
Study: NCT05510752

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Group Therapy
Description: CBGT is a 6-week group that meets weekly for 2-hours per week, where participants learn cognitive and behavioural techniques to enhance coping skills for their everyday anxieties.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Psychoeducation is the most common non-pharmacological treatment for perinatal distress, where participants learn about healthy infant milestones and how to implement self-care in their daily lives, which in turn reduces distress during the perinatal period.
Study: NCT05365477

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Empiric Therapy: Diet
Description: Diet: High water intake - at least 2.5 liters daily Reduce sugar-sweetened cola intake to ≤3 cans per week. Reduce salt intake to \<2000mg sodium daily Reduce red meat intake to two 4-ounce portions per week Normal calcium intake: 3 servings of dairy products (or their equivalents) per day Increase vegetable and fruit intake to ≥5 servings per day Reduce oxalate intake to \<100 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empiric Therapy: Drug
Description: Drug(s): indapamide 1.25mg and potassium citrate 15mEq daily.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Selective Therapy: Diet
Description: Diet:~Volume \<2.5L Increase fluid intake to ≥ 2.5L/d, based on specific urine volume~Calcium \>250mg male, \>200mg female Reduce red meat intake to two 4-oz portions/wk; reduce sodium intake to\<2000mg/d, avoid vitamin D + calcium supplements~Oxalate \>40mg Reduce dietary oxalate intake to \<100 mg/d; increase fiber intake to 25-35 g/d~Citrate \<450mg male, \<550mg female Reduce red meat intake to two 4-oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d~pH\<5.8 Reduce red meat intake to two 4-oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d~Uric acid \>800mg male, \>750mg female Reduce red meat intake to two 4- oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d~Sodium \>150mmol Reduce sodium intake to \<2000mg/d~Sulfate \> 80mEq or urine urea nitrogen \>14g Reduce red meat intake to three 3-4 oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selective Therapy: Drug
Description: Drug(s):~For calcium \>250mg male, \>200mg female: indapamide 1.25mg and potassium chloride 20mEq. At 1 month if persistent, then increase to indapamide 2.5mg and potassium chloride 20mEq. For citrate \<450mg male, \<550mg female: potassium citrate 15mEq BID. At 1 month if persistent, then increase to potassium citrate 30mEq BID. For pH\<5.8: potassium citrate 15mEq BID. At month if persistent, then increase to potassium citrate 30mEq BID. For uric acid \>800mg male, \>750mg female: allopurinol 300mg.~If both elevated calcium and low pH: indapamide 1.25mg and potassium citrate 15mEq BID If both elevated calcium and low citrate: indapamide 1.25mg and potassium citrate 15mEq BID
Study: NCT05199220

Intervention type: OTHER
Intervention: Questionnaire
Description: Participant must complete a questionnaire about injury during crossfit practice
Study: NCT05222607

Intervention type: DRUG
Intervention: IncobotulinumtoxinA
Description: IncobotulinumtoxinA injections for aesthetic indications.
Study: NCT06240091

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DISC-MA
Description: DISC-MA is a digital program that utilizes elements from validated psychotherapies (e.g., cognitive behavioral therapy), with a relational agent (Woebot) that engages users in conversations with responses that are selected from a list based on natural language processing.
Study: NCT06178926

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol was IV infused 1.0-1.5mg/Kg and then maintenance at 1.0-2.0mg/Kg/h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofol
Description: Ciprofol was IV infused 0.2- 0.3mg/Kg and then maintenance at 0.2-0.3mg/Kg/h
Study: NCT05384353

Intervention type: OTHER
Intervention: [18F]-SynVesT-1
Description: PET radioligand binding to synaptic vesicle protein 2A as a proxy for synaptic density

Intervention type: OTHER
Intervention: [18F]-SynVesT-1
Description: PET radioligand binding to synaptic vesicle protein 2A as a proxy for synaptic density

Intervention type: OTHER
Intervention: [18F]-SynVesT-1
Description: PET radioligand binding to synaptic vesicle protein 2A as a proxy for synaptic density

Intervention type: OTHER
Intervention: [18F]-SynVesT-1
Description: PET radioligand binding to synaptic vesicle protein 2A as a proxy for synaptic density

Intervention type: OTHER
Intervention: [18F]-SynVesT-1
Description: PET radioligand binding to synaptic vesicle protein 2A as a proxy for synaptic density
Study: NCT04756388

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strategy Development
Description: Participants engage in cognitive strategy discussions to develop new executive function strategies that can be used in daily life, and track their strategies between sessions. No computerized cognitive training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strategy Development
Description: Participants engage in cognitive strategy discussions to develop new executive function strategies that can be used in daily life, and track their strategies between sessions. No computerized cognitive training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training
Description: Participants practice computerized training exercises targeting executive functioning skills, and complete computerized exercises between sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Cognitive Training
Description: Participants practice computerized training exercises targeting executive functioning skills, and complete computerized exercises between sessions.
Study: NCT05545657

Intervention type: BEHAVIORAL
Intervention: Cognitive assessments
Description: Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Rey Auditory Verbal Learning Test (RAVLT), Boston Naming Test (BNT), Digit Span Test (DST), Trail Making Test (TMT).

Intervention type: BEHAVIORAL
Intervention: Cognitive assessments
Description: Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Rey Auditory Verbal Learning Test (RAVLT), Boston Naming Test (BNT), Digit Span Test (DST), Trail Making Test (TMT).

Intervention type: OTHER
Intervention: Simultaneous EEG-fMRI scan
Description: EEG recordings were conducted with a 64-channel MR-compatible EEG system (Electrical Geodesics Inc., Eugene, OR, USA) and an MR-compatible EEG cap (HydroCel Geodesic Sensor Nets), using ring-type sintered silver chloride electrodes with iron-free copper leads.

Intervention type: OTHER
Intervention: Simultaneous EEG-fMRI scan
Description: EEG recordings were conducted with a 64-channel MR-compatible EEG system (Electrical Geodesics Inc., Eugene, OR, USA) and an MR-compatible EEG cap (HydroCel Geodesic Sensor Nets), using ring-type sintered silver chloride electrodes with iron-free copper leads.

Intervention type: OTHER
Intervention: Multimodal magnetic resonance imaging
Description: 3D T1-weighted imaging, Resting-state fMRI, Diffusion tensor imaging, Arterial spin labeling.

Intervention type: OTHER
Intervention: Multimodal magnetic resonance imaging
Description: 3D T1-weighted imaging, Resting-state fMRI, Diffusion tensor imaging, Arterial spin labeling.

Intervention type: OTHER
Intervention: Peripheral blood neuropathology biomarkers assay
Description: Detecting the peripheral blood neuropathology biomarkers using single molecule array (Simoa) technique, including Aβ40, Aβ42, P-tau 181, P-tau 231, GFAP and NfL.

Intervention type: OTHER
Intervention: Peripheral blood neuropathology biomarkers assay
Description: Detecting the peripheral blood neuropathology biomarkers using single molecule array (Simoa) technique, including Aβ40, Aβ42, P-tau 181, P-tau 231, GFAP and NfL.
Study: NCT06422780

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maternal Role Preparation Training
Description: Maternal Role Preparation Training: Maternal Role Preparation Training (MRHE) is an occupational training programme aimed at increasing the competence of first-time mothers regarding motherhood. In this four-session programme, pregnant women will be provided with written materials, face-to-face talks and practical training covering topics related to their babies (maternal attachment, training on the sensory and developmental abilities of babies) and themselves (training on adopting a new role as a mother).The sessions will be applied 2 days a week, each session 1 hour, a total of 8 weeks-16 sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Awareness Centred Occupational Therapy Group
Description: Awareness Centred Occupational Therapy (FME); In FME, areas that affect the occupational performance of pregnant women in their daily lives will be identified and appropriate occupational therapy interventions will be applied. Awareness training on the applications will be given before starting the sessions. The sessions will be applied 2 days a week, each session 1 hour, a total of 8 weeks-16 sessions. Awareness training will be given before starting the sessions.
Study: NCT06375421

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MEMI (Memory Ecological Momentary Intervention) Spaced Retrieval
Description: Participants complete their initial learning session, and the subsequent retrieval sessions are spaced out over the course of the week (two short retrieval sessions each day) using MEMI. Then, they complete a 15-minute test for their memory of all of the trained items at the end of the week.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MEMI (Memory Ecological Momentary Intervention) Spaced Retrieval
Description: Participants complete their initial learning session, and the subsequent retrieval sessions are spaced out over the course of the week (two short retrieval sessions each day) using MEMI. Then, they complete a 15-minute test for their memory of all of the trained items at the end of the week.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Blocked Retrieval
Description: Participants will complete their initial learning session on the target words, then immediately receive all of the exposures to each of the items in a single block. They do not complete any more retrieval sessions until one week later, when they complete a 15-minute test for their memory of all of the trained items.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Blocked Retrieval
Description: Participants will complete their initial learning session on the target words, then immediately receive all of the exposures to each of the items in a single block. They do not complete any more retrieval sessions until one week later, when they complete a 15-minute test for their memory of all of the trained items.
Study: NCT05624294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS0159
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS0159
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS0159
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets administered orally
Study: NCT04997733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Description: The colonoscopy for FMT will be planned between 7 and 14 days after the last adalimumab or sub-cutaneous infliximab administration and 6 weeks +/- 7 days after the last intravenous infliximab administration 14 and 28 days following the last sub-cutaneous golimumab administration. After colon cleansing using polyethylene glycol, the patient will have a colonoscopy under general anesthesia. The patient will then receive either FMT (frozen preparation of 50g of stools in 300ml of saline (NaCl 0.9%), (FMT vehicle in the terminal ileum or the colon.~At W12 and W24 after first colonoscopy, the patient receives treatment by capsule (15 capsules contain 0.8g of stools by visit).

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham-transplantation (placebo)
Description: The colonoscopy for sham-transplantation will be planned between 7 and 14 days after the last adalimumab or sub-cutaneous infliximab administration and 6 weeks +/- 7 days after the last intravenous infliximab administration, 14 and 28 days following the last sub-cutaneous golimumab administration. After colon cleansing using polyethylene glycol, the patient will have a colonoscopy under general anesthesia. The patient will then receive either sham transplantation (frozen preparation of NaCl 0.9% with 10% glycerol) in the terminal ileum or the colon.~At S12 and S24 after first colonoscopy, the patient receives treatment by capsule (15 capsules contain placebo).
Study: NCT05172141

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI314(low dose)
Description: intravenously, once, on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI314(high dose)
Description: intravenously, once, on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI314(medium dose)
Description: intravenously, once, on Day 1

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenously, once, on Day 1
Study: NCT05573087

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aquatic Based Exercise
Description: 10 minutes of exercise with two 20 second sprints three days per week for 8 consecutive weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Land Based Exercise
Description: 10 minutes of exercise with two 20 second sprints three days per week for 8 consecutive weeks
Study: NCT04186299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Each patient will receive a buccal infiltration of 1.7mL of 1:100,000 clonidine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine Hydrochloride + Epinephrine
Description: Each patient will receive a buccal infiltration of 1.7mL of 4% articaine with 1:100,000 epinephrine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Articaine Hydrochloride + Epinephrine
Description: Each patient will receive a buccal infiltration of 1.7mL of 4% articaine with 1:100,000 epinephrine.
Study: NCT04643860

Intervention type: DIAGNOSTIC_TEST
Intervention: Differential Leucocyte Count (CLDC) device and algorithm
Description: Boold sample that detecting the early rise in leukocyte levels which has a characteristic set of ratios of leukocyte types, which identify the viral pathogen and distinguish it from a number of others. This test allows prediction of positives from full blood count results.